Dr. Anteneh A. Tesfaye, MD

Dr. Tesfaye practices at MedStar Washington Hospital Center in Washington, District of Columbia, part of MedStar Health.

Dr. Tesfaye's NPI, 1003128810, was assigned on July 9, 2010. Dr. Tesfaye holds Michigan license 4301095841.

Dr. Tesfaye's primary practice is MedStar Washington Hospital Center, at 110 Irving Street NW, Washington, DC 20010 in The District County. The practice phone is (202) 877-7000.

Dr. Tesfaye's primary practice is MedStar Washington Hospital Center in Washington, District of Columbia, part of MedStar Health. The medical group on file is MedStar Medical Group. Dmand AI also links Dr. Tesfaye to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tesfaye practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tesfaye's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tesfaye is board certified in hematology by the American Board of Internal Medicine. Dr. Tesfaye is licensed in Michigan.

CMS data shows 558 Medicare services from Dr. Tesfaye across 7 procedure codes in 2024, for 180 Medicare patients. Medicare paid $59,113 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 180 Medicare patients who saw Dr. Tesfaye in 2024. The largest group is 65 to 74, with 76 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 41% are also on Medicaid. Their average risk score is 2.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tesfaye's median patient age at 72, with 45% women.

In 2024, Dr. Tesfaye wrote 352 Medicare Part D claims for 74 patients. 76% of them were for generic drugs. CMS names the drug for 187 of them, across 12 drugs with 11 or more claims each, at $1,190,487 in total drug cost. In 2023, CMS named 209 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Tesfaye for performance year 2024, reported as part of a group.

Dmand AI links 18 papers to Dr. Tesfaye, published from 2014 to 2024. 2019 was the busiest year, with 4. The most frequent topics are Biomarkers, Tumor, Pancreatic Neoplasms and Antineoplastic Combined Chemotherapy Protocols. Dr. Tesfaye has published most often in Clin Adv Hematol Oncol. Dr. Tesfaye's most frequent co-authors are Aiwu Ruth He, MD, PhD, Mandana Kamgar, MD and Brandon George Smaglo, MD.

Dmand AI links Dr. Tesfaye to 10 clinical trials, 5 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Anal Canal Carcinoma, Anus Neoplasms and Cholangiocarcinoma. National Cancer Institute (NCI) sponsors the most, 8.

CMS Open Payments shows 87 general payments to Dr. Tesfaye from 23 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 29% of the total. Exelixis Inc. paid the most, $7,794. It also lists 3 research payments totaling $5,904 from 2017 to 2023.